Go Pro
NASDAQ:SRTA

Strata Critical Medical Q1 2026 Earnings Report

$5.32 -0.05 (-0.93%)
As of 03:58 PM Eastern

Strata Critical Medical EPS Results

Actual EPS
$0.03
Consensus EPS
-$0.04
Beat/Miss
Beat by +$0.07
One Year Ago EPS
N/A

Strata Critical Medical Revenue Results

Actual Revenue
$67.38 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Strata Critical Medical Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Strata Critical Medical Earnings Headlines

FDA Momentum is Building Around NNVC!
NanoViricides (NYSE: NNVC) just received regulatory approval to begin a Phase II trial of NV-387 Oral Gummies for Ebola in the DRC, now the country's largest outbreak on record with over 4,100 cases. NV-387 uses a host-mimetic nanoviricide platform designed to trap and neutralize viruses. Noble Capital Markets recently initiated coverage on NNVC with an Outperform rating and a $6 price target.tc pixel
See More Strata Critical Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Strata Critical Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Strata Critical Medical and other key companies, straight to your email.

About Strata Critical Medical

Blade Air Mobility, Inc. provides air transportation alternatives to the congested ground routes in the United States. It provides its services through charter and by-the-seat flights using helicopters, jets, turboprops, and amphibious seaplanes. The company was founded in 2014 and is headquartered in New York, New York.

View Strata Critical Medical Profile